Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages

  Pâquet, Sophie ^a   Fazli, Ladan ^b   Grosse, Laurent ^a   Verreault, Meĺanie ^a   Tet̂u, Bernard ^c   Rennie, Paul S ^b   Beĺanger, Alain ^a   Barbier, Olivier ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Université Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME REGULATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR CELL;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84858041020     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2064     Document Type: Article

References (20)

1. Jemal A, Center MM, DeSantis C, Ward EM 2010 Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907
2. Labrie F 2011 Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8:73-85
3. Balk SP, Knudsen KE 2008 AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
4. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL 2010 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765
5. Barbier O, Bélanger A 2008 Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 22:259-270 (Pubitemid 351611947)
6. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM 2011 Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71:1486-1496
7. Chouinard S, Pelletier G, Bélanger A, Barbier O 2004 Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 30: 717-725 (Pubitemid 40070159)
8. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GS 2008 Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate 68: 839-848 (Pubitemid 351845215)
9. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B, Thalmann GN2011 Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 71:453-460
10. Crnalic S, Hörnberg E, Wikström P, Lerner UH, Tieva A, Svensson O, Widmark A, Bergh A 2010 Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr Relat Cancer 17:885-895
11. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA 2011 Steroidogenic enzymes and stem cell markers are up-regulated during androgen deprivation in prostate cancer. Mol Med 17:657-664
12. Trudel D, Fradet Y, Meyer F, Têtu B 2010 Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol 41:1694-1701
13. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME 2011 Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 10:347-359
14. Chai J, Norng M, Modak C, Reavis KM, Mouazzen W, Pham J 2010 CCN1induces a reversible epithelial-mesenchymal transition in gastric epithelial cells. Lab Invest 90:1140-1151
15. Guillemette C, Lévesque E, Beaulieu M, Turgeon D, Hum DW, Bélanger A 1997 Differential regulation of two uridine diphosphoglucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 138:2998-3005
16. Kaeding J, Bouchaert E, Bélanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Bélanger A, Barbier O 2008 Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem J 410:245-253 (Pubitemid 351346182)
17. Chouinard S, Pelletier G, Bélanger A, Barbier O 2006 Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 147:5431-5442 (Pubitemid 44790598)
18. Ménard V, Eap O, Harvey M, Guillemette C, Lévesque E 2009 Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism. Hum Mutat 30:1310-1319
19. Satelli A, Li S 2011 Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68:3033-3046
20. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454